(Beijing Comprehensive News) U.S. Intelligence officials reportedly told the Senators who participated in the formulation of the Biological Safety Act at the end of February that China Pharmaceutical Company Yao Kanto transferred American knowledge and property rights to China without consent.

Reuters on Thursday (March 28) quoted anonymous sources reported that the FBI, the Office of the State Council, and the Office of the National Intelligence Director, confidentially notified a dozen senators at the end of February.These officials refer to the drugs of Ming Kangde and other Chinese entities to engage in activities that violate US national security interests in the United States.

Sources said that one of their concerns is that the recent intelligence reflected that Yao Ming Kangde transferred the knowledge and property rights of American customers to Chinese officials without consent.

Sources did not disclose information about customers' names, nor did they disclose the specific content of relevant knowledge and property rights.

The U.S. government is worried that some Chinese biotechnology companies will provide technology or research and development for the Chinese military.The U.S. Senate is proposing a new bill to restrict the US government with funds to these Chinese companies.The Land Safety Committee of the US Congress Senate was

Bloomberg reported that Yin Ming Kangde had previously denied that there was any improper relationship with the Chinese government or the military, and said that the United States' allegations against the company were wrong.

A spokesman for Yaoming Kant said that the situation of transferring data or intellectual property rights to any American customers to China is unaware of it, and it is said that the protection of customers' information is very important to the company.Instructions to store this information. "The spokesman also emphasized that Yaoming Kangde respects and fully abides by the requirements of the US Federation and the state government.

The Chinese Embassy in the United States said that the US Congress's statement on Pharmaceutical Kant's threat to US national security has no basis, and said that if anyone thinks that Yaoming Kant or its affiliated company violates the laws and property rights of knowledge and property,Provide convincing evidence to support their claims.

Reuters issued a report on Thursday afternoon, the stock price listed in Hong Kong has narrowed the increase of nearly 5%earlier, and closes by 1%.Public information shows that in the past six months, Yaoming Kant's stock price has declined and has fallen by more than 45%.

The scope of business of Yao Ming Kant from R & D to pharmaceutical raw materials and drug production, its customers include large pharmaceutical companies and small biotechnology companies.Yaoming Kant's sales last year from the United States.